Last reviewed · How we verify
NCT02202304
The Effects of Chlorhexidine/Thymol Varnish on Partial Denture Patient
Phase 4 trial testing Chlorhexidine/Thymol varnish in Periodontal Disease. Withdrawn.
10 September 2019
Quick facts
| Lead sponsor | Rosa Moreno Lopez |
|---|---|
| Phase | Phase 4 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | prevention |
| Start date | 10 September 2017 |
| Primary completion | 10 September 2019 |
| Estimated completion | 10 December 2020 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Chlorhexidine/Thymol varnish — full drug profile →
Conditions studied
- Periodontal Disease — all drugs for Periodontal Disease →
- Caries — all drugs for Caries →
Sponsor
Rosa Moreno Lopez — full company profile →
Who can join
18 and older, any sex, with Periodontal Disease or Caries. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cervitec, a chlorhexidine based varnished has been proven to reduce caries risk in younger populations. This study wants to investigate if the use of this product would reduce the risk of losing abutment teeth on patients that are wearing partial dentures as the literature has proven that these teeth are more prone to caries and periodontal disease. The primary objectives of this research project are to: 1. Assess if the topical application of CHX/thymol varnish every three months on partial denture abutment teeth results in a clinicallu significant decrease in any loss of attachment compared to no application, and 2. Assess if the topical application of CHX/thymol vanirhs every three months on partial denture abutment teeth results in a clinically significant decrease in carious lesion development or progression compared to no application. The secondary objectives of this research project are to: 1\. Assess of the topical application of CHX/thymol varnish every three months on partial denture abutment teeth compared to no application results in a clinically significant difference in: 1. Bleeding on probing (BoP). 2. Plaque formation. 3. Periodontal pocket depths. 4. Microbial composition and GCF cytokine profile of the sub gingival environment. 5. The patients self perception of oral health.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT02202304
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Periodontal Disease
Currently open trials in the same condition.
- NCT07421960 — Investigation of the Relationship Between Periodontitis and Sleep Quality · recruiting
- NCT07446127 — Adjunctive Diode Laser Therapy in Non-Surgical Periodontal Therapy · NA · recruiting
- NCT07258303 — Oral-Spray Bacillus Spore Probiotics for Periodontal Disease Prevention and Supprotive Treatment in the Elderly · NA · recruiting
- NCT07257887 — Assessment of the Efficacy and Safety of OROXID® Oral Solution in Patients With Periodontitis · NA · recruiting
- NCT07262606 — Salivary Mitofusin-1 Levels in Periodontitis: Associations With Disease Severity, Smoking, and Treatment Response · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02202304 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rosa Moreno Lopez
- Last refreshed: 15 May 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02202304.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing